Sandoz Gets U.S. Distribution Rights for Two Hospital-Injectable Medicines

   By Stephen Nakrosis 
 

Sandoz on Monday said it has acquired the U.S. distribution rights to a pair of hospital-injectable medicines "to reinforce the company's strategy to grow its injectables portfolio and overall offerings in the hospital setting."

Sandoz, a division of Novartis, said it acquired the U.S. distribution rights to daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG.

Daptomycin is used in the treatment of certain infections and is the generic version of Cubicin. Fosaprepitant, the generic prodrug of Emend, is used to prevent nausea and vomiting in chemotherapy patients, the company said.

Sandoz President Carol Lynch said, "Our ambition is to make Sandoz the world's leading and most valued generics company. To realize that ambition in the U.S. market, we are focusing on specific segments such as hospitals and oncology clinics with generic and branded generic injectables, where we can do the most to pioneer access for patients."

--Write to Stephen Nakrosis at [e-mail]

(END) Dow Jones Newswires

March 23, 2020 16:52 ET (20:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.